Dear Dr Whitehouse

Thank you for your letter of 24 October 2017, responding to the Committee's request for further information on the above research and submitting revised documentation.

The further information has been considered on behalf of the Committee by the Chair.

We plan to publish your research summary wording for the above study on the HRA website, together with your contact details. Publication will be no earlier than three months from the date of this opinion letter. Should you wish to provide a substitute contact point, require further

<table>
<thead>
<tr>
<th>Study title:</th>
<th>STRESS-L: STudy into the REversal of Septic Shock with Landiolol (Beta Blockade)</th>
</tr>
</thead>
<tbody>
<tr>
<td>REC reference:</td>
<td>17/EE/0368</td>
</tr>
<tr>
<td>Protocol number:</td>
<td>STRESS-L</td>
</tr>
<tr>
<td>EudraCT number:</td>
<td>2017-001785-14</td>
</tr>
<tr>
<td>IRAS project ID:</td>
<td>213669</td>
</tr>
</tbody>
</table>

Please note: This is the favourable opinion of the REC only and does not allow you to start your study at NHS sites in England until you receive HRA Approval.
information, or wish to make a request to postpone publication, please contact hra.studyregistration@nhs.net outlining the reasons for your request.

**Confirmation of ethical opinion**

On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above research on the basis described in the application form, protocol and supporting documentation as revised subject to the conditions specified below.

**Conditions of the favourable opinion**

The REC favourable opinion is subject to the following conditions being met prior to the start of the study.

Management permission must be obtained from each host organisation prior to the start of the study at the site concerned.

Management permission should be sought from all NHS organisations involved in the study in accordance with NHS research governance arrangements. Each NHS organisation must confirm through the signing of agreements and/or other documents that it has given permission for the research to proceed (except where explicitly specified otherwise).


Where a NHS organisation’s role in the study is limited to identifying and referring potential participants to research sites ("participant identification centre"), guidance should be sought from the R&D office on the information it requires to give permission for this activity.

For non-NHS sites, site management permission should be obtained in accordance with the procedures of the relevant host organisation.

Sponsors are not required to notify the Committee of management permissions from host organisations.

**Registration of Clinical Trials**

All clinical trials (defined as the first four categories on the IRAS filter page) must be registered on a publically accessible database within 6 weeks of recruitment of the first participant (for medical device studies, within the timeline determined by the current registration and publication trees).

There is no requirement to separately notify the REC but you should do so at the earliest opportunity e.g. when submitting an amendment. We will audit the registration details as part of the annual progress reporting process.
To ensure transparency in research, we strongly recommend that all research is registered but for non-clinical trials this is not currently mandatory.

If a sponsor wishes to request a deferral for study registration within the required timeframe, they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials will be registered, however, in exceptional circumstances non registration may be permissible with prior agreement from the HRA. Guidance on where to register is provided on the HRA website.

Clinical trial authorisation must be obtained from the Medicines and Healthcare products Regulatory Agency (MHRA).

The sponsor is asked to provide the Committee with a copy of the notice from the MHRA, either confirming clinical trial authorisation or giving grounds for non-acceptance, as soon as this is available.

It is the responsibility of the sponsor to ensure that all the conditions are complied with before the start of the study or its initiation at a particular site (as applicable).

Ethical review of research sites

NHS sites

The favourable opinion applies to all NHS sites listed in the application, subject to management permission being obtained from the NHS/HSC R&D office prior to the start of the study (see "Conditions of the favourable opinion" below).

Non-NHS sites

The Committee has not yet completed any site-specific assessment (SSA) for the non-NHS research site(s) taking part in this study. The favourable opinion does not therefore apply to any non-NHS site at present. We will write to you again as soon as an SSA application(s) has been reviewed. In the meantime no study procedures should be initiated at non-NHS sites.

Approved documents

The final list of documents reviewed and approved by the Committee is as follows:

<table>
<thead>
<tr>
<th>Document</th>
<th>Version</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>GP/consultant information sheets or letters [GP Letter]</td>
<td>1.0</td>
<td>10 August 2017</td>
</tr>
<tr>
<td>IRAS Application Form [IRAS_Form_01092017]</td>
<td></td>
<td>01 September 2017</td>
</tr>
<tr>
<td>Other [REC cover letter]</td>
<td>1.0</td>
<td>20 October 2017</td>
</tr>
<tr>
<td>Other [patient information sheet_tracked changes]</td>
<td>2.0</td>
<td>17 October 2017</td>
</tr>
<tr>
<td>Other [SHORT PIS_tracked changes]</td>
<td>2.0</td>
<td>17 October 2017</td>
</tr>
<tr>
<td>Other [Legal Representative Information Sheet_tracked changes]</td>
<td>2.0</td>
<td>17 October 2017</td>
</tr>
<tr>
<td>Other [Patient Consent Form_tracked changes]</td>
<td>2.0</td>
<td>17 October 2017</td>
</tr>
<tr>
<td>Other [Legal Rep Consent Form_tracked changes]</td>
<td>2.0</td>
<td>17 October 2017</td>
</tr>
<tr>
<td>Participant consent form [Patient Consent Form]</td>
<td>2.0</td>
<td>17 October 2017</td>
</tr>
</tbody>
</table>
Statement of compliance

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

After ethical review

Reporting requirements

The attached document “After ethical review – guidance for researchers” gives detailed guidance on reporting requirements for studies with a favourable opinion, including:

- Notifying substantial amendments
- Adding new sites and investigators
- Notification of serious breaches of the protocol
- Progress and safety reports
- Notifying the end of the study

The HRA website also provides guidance on these topics, which is updated in the light of changes in reporting requirements or procedures.

User Feedback

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website: [http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/](http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/)

HRA Training

We are pleased to welcome researchers and R&D staff at our training days – see details at [http://www.hra.nhs.uk/hra-training/](http://www.hra.nhs.uk/hra-training/)
With the Committee’s best wishes for the success of this project.

Yours sincerely

Dr Niki Bannister
Chair

Email:NRESCommittee.EastofEngland-Essex@nhs.net

Enclosures: “After ethical review – guidance for researchers”

Copy to: Miss Nafisa Boota
Dr Chris Counsell, University Hospital Birmingham NHS Foundation Trust